SERVICES-COMPUTER PROGRAMMING, DATA PROCESSING, ETC.
Health Catalyst, Inc Common Stock
HCAT
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platform, analytics applications and support services and generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.
Last trade$1.36
Day change-$0.02 (-1.45%)
Day range$1.32 – $1.40
Volume101,251
Market cap$105M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$105.09M
Price / earnings
—
Price / book
0.72×
Price / sales
0.39×
EV / sales
0.19×
EV / EBITDA
10.44×
Profitability
Earnings per share
-$2.65
Return on assets
-85.12%
Return on equity
-138.81%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
1.7×
Quick ratio
1.7×
Cash ratio
0.69×
Cash flow
Price / cash flow
3.92×
Price / free cash flow
4.09×
Free cash flow
$25.71M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for HCAT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$56.28M
$70.49M
$70.76M
$74.68M
$76.32M
$80.72M
$79.41M
$79.61M
Cost of revenue
$32.24M
$35.63M
$35.29M
$35.3M
$38.51M
$42.48M
$43.18M
$44.92M
Gross profit
$24.04M
$34.86M
$35.46M
$39.38M
$37.82M
$38.24M
$36.24M
$34.69M
Selling, general and administrative
$20.56M
$22.29M
$24.55M
$21.22M
$30.43M
$21.49M
$28.9M
$26.92M
Research and development
$9.5M
$11.03M
$9.78M
$9.91M
$12.28M
$12.39M
$15.19M
$15M
Total operating expenses
$39.79M
$71.34M
$141.94M
$125.46M
$55.33M
$75.34M
$56.41M
$52.19M
Operating income
-$15.75M
-$36.48M
-$106.48M
-$86.08M
-$17.51M
-$37.09M
-$20.17M
-$17.5M
Interest expense
-$540K
-$3.74M
$0
$0
-$4.68M
-$3.8M
$0
$0
Income before taxes
$40.1M
-$40.22M
-$110.61M
-$90.65M
-$22.19M
-$40.9M
-$23.53M
-$20.05M
Income taxes
-$393K
$315K
$414K
$379K
$41K
$81K
$215K
$625K
Net income
$40.5M
-$40.54M
-$111.03M
-$91.03M
-$22.23M
-$40.98M
-$23.74M
-$20.67M
Net income attributable to common shareholders
$40.5M
-$40.54M
-$111.03M
-$91.03M
-$22.23M
-$40.98M
-$23.74M
-$20.67M
EBITDA
-$6.02M
$1.55M
$1.14M
$8.26M
-$4.9M
$4.36M
-$7.85M
-$7.23M
Basic earnings per share
$0.54
-$0.55
-$1.53
-$1.28
-$0.32
-$0.59
-$0.35
-$0.33
Diluted earnings per share
$0.53
-$0.55
-$1.53
-$1.28
-$0.32
-$0.59
-$0.35
-$0.33
Recent news
Company coverage with links to the original publishers.
Health Catalyst reported Q3 2026 revenue of $56.28 million, down 26.3% year-over-year, with EPS of -$0.03 versus $0.06 in the prior year quarter. While revenue slightly beat consensus estimates by 1.98%, EPS missed by 50%. Key metrics showed weakness across both segments: Professional Services revenue declined 35.7% YoY, and Technology revenue fell 21.8% YoY. The stock has a Zacks Rank #3 (Hold) rating and underperformed the S&P 500 by 9.3% over the past month.
Schrodinger (SDGR) beat earnings expectations with a loss of $0.5 per share versus consensus estimate of $0.66, representing a 24.24% earnings surprise. The company also exceeded revenue estimates at $64.49 million, up from $54.32 million year-over-year. Despite outperforming the market by 52% year-to-date, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. Health Catalyst (HCAT), a peer in the Medical Info Systems industry, is expected to report results on November 5.
Europe's clinical data analytics market is projected to reach USD 105.6 billion by 2031, growing at a 27% CAGR through 2033. Growth is driven by healthcare digitalization, AI adoption, cloud deployment, and regulatory initiatives like the European Health Data Space. Software and cloud-based solutions lead the market, with healthcare providers and payers increasingly investing in analytics for improved patient outcomes and operational efficiency.
Health Catalyst, Inc. announced the appointment of Simeon Kohl as Chief Executive Officer and President effective September 14, 2026. As part of his employment inducement, Kohl was granted 2,747,385 restricted stock units vesting over approximately two years, with the first tranche of 915,975 RSUs vesting after one year. Kohl also purchased 59,000 shares of Health Catalyst common stock through open market purchases.
Health Catalyst, Inc. (Nasdaq: HCAT) announced it will release its first quarter 2026 operating results on May 11, 2026, followed by a conference call. The company also appointed Steve Nelson, President of Aetna, to its Board of Directors effective May 1, 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.